Loading...
XNAS
EPIX
Market cap9mUSD
Oct 08, Last price  
0.20USD
Name

ESSA Pharma Inc

Chart & Performance

D1W1MN
XNAS:EPIX chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
39.33%
Rev. gr., 5y
%
Revenues
0k
000021700000000
Net income
-29m
L+7.38%
00-1,823,9290-13,140,000-4,499,000-11,630,000-10,441,000-23,445,000-36,805,461-35,103,000-26,582,343-28,542,821
CFO
-23m
L+14.83%
00-2,081,1930-15,300,969-17,354,811-10,218,046-12,249,935-16,983,152-25,415,611-28,704,169-19,781,716-22,716,199

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
IPO date
Feb 22, 2021
Employees
50
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT